NYSE · LLY
Eli Lilly and Company
$1,417.54+$43.84 (+3.19%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
Loading market information…
NASDAQ · INDV · USD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Indivior Pharmaceuticals Inc’s quoted price sits in the upper half of its reported 52-week range, 17.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Indivior Pharmaceuticals Inc’s forward annual dividend is $0.95 per share, paid semi-annual. The forward yield is 2.69% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Indivior Pharmaceuticals Inc’s next earnings report is currently expected on Feb 25, 2027, with estimated earnings per share of $0.99. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Indivior Pharmaceuticals Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 04:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 31, 2025 | $0.51+96.15% vs estimate | $302.00M+18.32% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | $0.41+86.36% vs estimate | $266.00M+9.78% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | $0.320.0% vs estimate | $299.00M+24.51% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $48.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,417.54+$43.84 (+3.19%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
$273.20-$2.00 (-0.73%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 3.13% below the high.
$294.89+$4.10 (+1.41%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.29% below the high.
$149.52+$3.19 (+2.18%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
$406.97-$3.94 (-0.96%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.84% below the high.
$45.34-$0.03 (-0.07%)
Alkermes plc’s quoted price sits in the upper half of its reported 52-week range, 18.56% below the high.
$41.92+$0.08 (+0.19%)
Supernus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.76% below the high.
$23.80-$0.23 (-0.96%)
Collegium Pharmaceutical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.14% below the high.
